DSM Chinese investment
This article was originally published in The Tan Sheet
Executive SummaryNutritional and drug ingredient manufacturer Royal DSM agrees to acquire a 10 percent stake in North China Pharmaceutical Group Corporation Ltd. and to establish a joint venture to manufacture vitamin C products. The Netherlands-based DSM says March 19 it will have a 30 percent stake in the vitamin C joint venture, plus 51 percent ownership of separate partnerships with the Hebei Province-based Chinese firm to develop active and intermediate pharmaceutical ingredients for anti-infective drugs. DSM's total cash investment will amount to approximately $110 million in the agreements the firms expect to start implementing in the second half of 2009
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.